Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
ChiCTR2200059190Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: 2-year overall survival. Started Aug 2022; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2200059190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059190.